GlobeNewswire·Mar 24, 2026, 8:30 AM ET

CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer

CytoDyn Inc. presented new preclinical data at the AACR Special Conference in Cancer Research: Brain Cancer demonstrating that leronlimab-mediated CCR5 inhibition enhances the response to temozolomide & radiation in glioblastoma multiforme (GBM).
Research indicates CCR5 expression is significantly elevated in primary GBM tumors compared to normal brain tissue & correlates with poor prognosis, hypoxic tumor core signatures, & mesenchymal GBM subtypes.
CCR5 expression aligns with markers of T-cell exhaustion & immune suppressive mediators, including PD-1, PD-L1, TIM3, PTX3, & S100A4.
In human GBM cell lines, CCR5 inhibition with leronlimab or maraviroc showed functional synergy with temozolomide to enhance tumor cell killing & increased radiation-induced cytotoxicity.
Metabolic profiling revealed that CCR5 inhibition reduces oxygen consumption rate in a dose-dependent manner, suggesting modulation of glycolytic programs that contribute to an immunosuppressive tumor microenvironment.
Leronlimab has demonstrated a favorable safety profile in clinical studies & the ability to cross the blood-brain barrier in non-human primate models.
The observed synergy with standard-of-care therapies supports CytoDyn's plan to initiate a pilot study evaluating leronlimab in glioblastoma.
The findings were presented in poster A002 by Ritika Harish on March 23, 2026, with a copy available on CytoDyn's website.